Ghana is targeting the production of its first locally manufactured vaccine in 2027, as government steps up efforts to reduce dependence on imported vaccines ahead of the country’s eventual exit from international immunisation support.
The National Vaccine Institute (NVI) has identified the Tetanus-Diphtheria vaccine as one of two biological products Ghana is expected to manufacture in 2027, alongside Anti-Tetanus Serum.
The development, disclosed by NVI Chief Executive Officer Dr Sodzi Sodzi-Tettey ahead of the commissioning of Ghana’s new vaccine research laboratories at the Noguchi Memorial Institute for Medical Research (NMIMR), signals a potentially significant shift in the country’s pharmaceutical manufacturing ambitions.
President John Dramani Mahama, who commissioned the vaccine research and human identification laboratories on Wednesday, November 18, also disclosed that government was preparing for the financial implications of Ghana’s eventual transition out of support from Gavi, the Vaccine Alliance, by January 2030.
He revealed that government would spend approximately US$46 million on vaccines for childhood immunisation in 2026, underscoring the financial demands of maintaining the country’s immunisation programme.
The President’s disclosure raises questions about the sustainability of Ghana’s vaccine financing arrangements as international support declines and the country assumes greater responsibility for procuring essential vaccines.
The newly commissioned vaccine research facility, comprising messenger RNA (mRNA) and protein laboratories, is expected to provide the scientific infrastructure needed to accelerate local vaccine research and development.
Ghana is among only five African countries currently using mRNA technology for vaccine research and development, according to the President.
Mr Mahama also disclosed that the National Vaccine Institute had trained five Ghanaian scientists in Brussels and Accra to strengthen local expertise and build capacity for training additional researchers.
The scientists were drawn from the Noguchi Memorial Institute, the West African Centre for Cell Biology of Infectious Pathogens, the Kumasi Centre for Collaborative Research and the University of Health and Allied Sciences.
He further revealed that the NVI was in discussions with a European partner over possible collaboration in cancer vaccine research using mRNA technology.
Two local companies selected
Beyond the research infrastructure, Ghana is also positioning local pharmaceutical companies to enter vaccine manufacturing.
President Mahama disclosed that Atlantic Lifesciences and DEK Laboratories had been selected to develop vaccines as part of the country’s efforts to establish a domestic manufacturing industry.
The National Vaccine Institute had earlier indicated that the two companies would require at least US$100 million to establish and equip their manufacturing facilities.
The institute also disclosed that US$50 million was allocated in August 2025 to support vaccine manufacturing.
The development builds on an earlier milestone achieved in May 2025, when the NVI, in collaboration with Atlantic Lifesciences, manufactured Ghana’s first biological product, snake venom anti-serum.
The institute estimates that approximately 10,000 people suffer snakebites annually in Ghana, making local production of the anti-serum particularly relevant to rural healthcare delivery.
The planned production of Anti-Tetanus Serum and the Tetanus-Diphtheria vaccine in 2027 is expected to extend that progress into vaccine manufacturing.
Mahama calls for public support for clinical trials
The President also used the commissioning ceremony to appeal to Ghanaians to support clinical trials, describing public participation as indispensable to the country’s vaccine development ambitions.
He recalled how plans to conduct Ebola vaccine trials in Ghana’s Volta Region were abandoned following public opposition fuelled by fears that residents were being used as guinea pigs.
The trials were subsequently moved to another African country, depriving Ghanaian researchers of an opportunity to participate in the process.

President Mahama argued that Ghana could not develop its own vaccines if citizens refused to participate in properly conducted clinical research.
“Nobody will do the clinical trials for us to develop vaccines in our country,” he said.
He recalled Africa’s difficulties accessing COVID-19 vaccines during the pandemic, when wealthier countries prioritised their domestic needs before making supplies available to developing countries.
The experience, he said, reinforced the need for African countries to build their own vaccine research and manufacturing capabilities.
Government has also allocated US$1 billion to develop pharmaceutical and biomanufacturing hubs in the Eastern, Central and Volta regions under the Seventh Pillar of the New Economy programme.
The broader ambition is to position Ghana as a pharmaceutical manufacturing centre for West Africa and the wider African continent.
Source: www.kumasimail.com






























































